“This new relationship with QuesGen Systems is an important milestone for ImmunArray, particularly at a time when we are expanding both our revenues and investment base.”
Burlingame, CA (PRWEB) April 06, 2016
QuesGen Systems, Inc., a provider of research services to organizations and investigators developing treatments for brain health and Traumatic Brain Injury (TBI), is expanding their business capabilities and is pleased to announce the formation of a business relationship with ImmunArray, a privately held molecular diagnostics company co-headquartered in Rehovot, Israel and Richmond, Virginia.
ImmunArray, which has developed and launched the first of a suite of products for diagnosis and management of Systemic Lupus Erythematosus and is developing novel sets of markers for TBI, will use the QuesGen platform to support the development and exploration of next-generation biomarker-based diagnosis and monitoring for both autoimmune disease and TBI. The company is currently conducting joint research in collaboration with leading medical centers in the United States and Israel in both fields.
“This new relationship with QuesGen Systems is an important milestone for ImmunArray, particularly at a time when we are expanding both our revenues and investment base,” said Donna Edmonds, CEO and chairman of the board, ImmunArray. “QuesGen’s expansive database and analytic capabilities will not only help us validate our work from a quantitative standpoint in Lupus, especially as we contemplate expanded studies and a registry, but also further enhance our data management and analysis capabilities as we broaden our study populations and clinical data collection in both Lupus and TBI populations. We look forward to tapping QuesGen’s expertise and resources.”
About ImmunArray: Co-located in Rehovot, Israel and Richmond, Va., ImmunArray is a privately funded molecular diagnostics company dedicated to the development of novel blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. The company designs and analyzes sets of biomarkers known to be linked to a particular condition and develops tests on platforms that are most appropriate to facilitate the adoption of additional tests. The company, which introduced its first commercial tests, is currently conducting research in collaboration with leading clinicians and medical centers in the U.S. and Israel. The company was a grant recipient of the GE-NFL Head Health Challenge as well as secured additional corporate research funding to conduct research into the use of biomarkers to identify traumatic brain injury. For more information about SLE-Key® and ImmunArray, visit http://www.immunarray.com.
About QuesGen: QuesGen Systems, Inc. (http://www.quesgen.com) provides data management and study resources to organizations, with the primary focus on TBI and brain health. QuesGen is working with Track-TBI (11 medical centers across the US), CENTER-TBI (72 centers across Europe), CENTER-TBI/China (40 centers in China), CARE (Prospective TBI study in 30,000 college athletes) and many others.
For more information about QuesGen Systems, please contact Barbara Maley, 650-727-0611; email: barbara.maley(at)quesgen(dot)com